Insights From the PLCO Trial About Prostate Cancer Screening

被引：2
|
作者：
Gulati, Roman [1 ]
Albertsen, Peter C. [2 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave North,M2-B230,POB 19024, Seattle, WA 98109 USA
[2] Univ Connecticut, Ctr Hlth, Dept Surg, Div Urol, Farmington, CT USA
来源：
CANCER | 2017年 / 123卷 / 04期
关键词：
RANDOMIZED PROSTATE; MORTALITY; ERSPC;
D O I：
10.1002/cncr.30472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：546 / 548
页数：3
相关论文
共 50 条
  • [21] FAMILY HISTORY AND INCREASED RISK OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN THE PLCO CANCER SCREENING TRIAL
    Bernstein, Adrien
    Golan, Ron
    Shoag, Jonathan
    Dinerman, Brian
    Hu, Jim C.
    JOURNAL OF UROLOGY, 2017, 197 (04): : E897 - E897
  • [22] Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Weissfeld, JL
    Fagerstrom, RM
    O'Brien, B
    CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 390S - 399S
  • [23] PROSTATE CANCER DETECTION WITH DIGITAL RECTAL EXAM IN THE PROSTATE LUNG COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Halpern, Joshua
    Shoag, Jonathan
    Mittel, Sameer
    Lipsitz, Stuart
    Ballman, Karla
    Hu, Jim
    JOURNAL OF UROLOGY, 2016, 195 (04): : E548 - E549
  • [24] PATTERN OF PSA CHANGE DURING SERIAL SCREENING IN THE PLCO CANCER SCREENING TRIAL AFFECTS PROSTATE CANCER RISK
    Grubb, Robert L., III
    Black, Amanda
    Reding, Douglas
    Hickey, Thomas
    Pinsky, Paul F.
    Church, Timothy R.
    Izmirlian, Grant
    Riley, Thomas
    Mabie, Jerome
    Ragard, Lawrence R.
    Berg, Christine D.
    Prorok, Philip C.
    Crawford, E. David
    Andriole, Gerald L., Jr.
    JOURNAL OF UROLOGY, 2009, 181 (04): : 811 - 812
  • [25] Measuring the impact of HIPAA in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
    Marcus, PM
    Miedzinksi, M
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (02) : 549 - 549
  • [26] The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource
    Zhu, Claire S.
    Huang, Wen-Yi
    Pinsky, Paulf F.
    Berg, Christine D.
    Sherman, Mark
    Yu, Kelly J.
    Carrick, Danielle M.
    Black, Amanda
    Hoover, Robert
    Lenz, Petra
    Williams, Craig
    Hawkins, Laura
    Chaloux, Matthew
    Yurgalevitch, Susan
    Mathew, Sunitha
    Miller, Amy
    Olivo, Vanessa
    Khan, Asia
    Pretzel, Shannon M.
    Multerer, Deborah
    Beckmann, Patricia
    Broski, Karen G.
    Freedman, Neal D.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (12) : 1635 - 1642
  • [27] Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Miller, AB
    Yurgalevitch, S
    Weissfeld, JL
    CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 400S - 406S
  • [28] Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial
    Pinsky, Paul F.
    Parnes, Howard L.
    Andriole, Gerald
    BJU INTERNATIONAL, 2014, 113 (02) : 254 - 259
  • [29] Body mass index and impact on PSA screening and prostate cancer detection in the PLCO trial
    Grubb, RL
    Levin, DL
    Pinsky, PF
    Mabie, J
    Riley, TL
    Greenlee, R
    Urban, DA
    Ragard, LR
    Crawford, ED
    Andriole, GL
    JOURNAL OF UROLOGY, 2006, 175 (04): : 155 - 155
  • [30] Determinants of radical prostatectomy in the prostate, lung, colorectal, ovarian (PLCO) cancer screening trial
    Miller, David C.
    Church, Timothy R.
    Hickey, Thomas
    Greenlee, Robert T.
    Lzmirlian, Grant
    Mabie, Jerome
    Riley, Thomas L.
    Ragard, Lawrence
    Prorok, Philip C.
    Berg, Christine D.
    Crawford, E. David
    Andriole, Gerald L.
    Grubb, Robert L.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 29 - 29
12345